Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Paclitaxel"" wg kryterium: Temat


Tytuł :
Bioequivalence assessment of high-capacity polymeric micelle nanoformulation of paclitaxel and Abraxane® in rodent and non-human primate models using a stable isotope tracer assay.
Autorzy :
Hwang D; Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, 27599, United States.
Vinod N; Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, 27599, United States; Joint UNC/NC State Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC, 27599, United States.
Skoczen SL; Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, MD, 21702, United States.
Ramsey JD; Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, 27599, United States.
Snapp KS; Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, MD, 21702, United States.
Montgomery SA; Department of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, United States.
Wang M; Biomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, United States.
Lim C; Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, 27599, United States.
Frank JE; Biomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, United States.
Sokolsky-Papkov M; Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, 27599, United States.
Li Z; Biomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, United States.
Yuan H; Biomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, United States.
Stern ST; Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, MD, 21702, United States.
Kabanov AV; Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, 27599, United States; Laboratory of Chemical Design of Bionanomaterials, Faculty of Chemistry, M. V. Lomonosov Moscow State University, Moscow, 119992, Russia. Electronic address: .
Pokaż więcej
Źródło :
Biomaterials [Biomaterials] 2021 Nov; Vol. 278, pp. 121140. Date of Electronic Publication: 2021 Oct 02.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Agents, Phytogenic*
Paclitaxel*
Albumin-Bound Paclitaxel ; Animals ; Cell Line, Tumor ; Drug Carriers ; Isotopes ; Macaca mulatta ; Micelles ; Rats ; Rodentia ; Therapeutic Equivalency
Czasopismo naukowe
Tytuł :
[Multi-center real world study of the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced breast cancer].
Autorzy :
Sang D; Department of Medical Oncology, Beijing Sanhuan Cancer Hospital, Beijing 100122, China.
Zhou H; Department of Medical Oncology, Beijing Sanhuan Cancer Hospital, Beijing 100122, China.
Zong H; Department of Medical Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Yang H; Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding 071000, China.
Lu QR; Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Fan SM; Department of Medical Oncology, Beijing Sanhuan Cancer Hospital, Beijing 100122, China.
Wang YC; Department of Medical Oncology, Beijing Sanhuan Cancer Hospital, Beijing 100122, China.
Song LH; Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
Yuan P; Special Medical Department, National Cancer Center /National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Pokaż więcej
Źródło :
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2021 Oct 23; Vol. 43 (10), pp. 1114-1121.
Typ publikacji :
Journal Article
MeSH Terms :
Albumin-Bound Paclitaxel*
Triple Negative Breast Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Humans ; Neoplasm Recurrence, Local ; Paclitaxel
Czasopismo naukowe
Tytuł :
Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models.
Autorzy :
Chen H; Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Huang S; Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Wang H; Department of Pharmacy, Inner Mongolia Medical University, Huhhot, China.
Chen X; Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Zhang H; Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Xu Y; Shanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China.
Fan W; Department of Pharmacy, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China.
Pan Y; Shanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China.
Wen Q; Shanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China.
Lin Z; Shanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China.
Wang X; Shanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China.
Gu Y; Shanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China.
Ding B; School of Pharmacy, Jiaxing College, Jiaxing, China.
Chen J; Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.; Department of Pharmacy, Inner Mongolia Medical University, Huhhot, China.
Wu X; Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.; Shanghai Wei Er Biopharmaceutical Technology Co., Ltd, Shanghai, China.
Pokaż więcej
Źródło :
Drug delivery [Drug Deliv] 2021 Dec; Vol. 28 (1), pp. 1067-1079.
Typ publikacji :
Journal Article
MeSH Terms :
Albumin-Bound Paclitaxel/*pharmacology
Antineoplastic Agents/*pharmacology
Albumin-Bound Paclitaxel/administration & dosage ; Albumin-Bound Paclitaxel/adverse effects ; Albumin-Bound Paclitaxel/pharmacokinetics ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Cell Line, Tumor ; Cell Proliferation ; Chemistry, Pharmaceutical ; Drug Carriers ; Drug Liberation ; Drug Stability ; Female ; Mice ; Mice, Inbred ICR ; Nanoparticles ; Particle Size ; Random Allocation ; Surface Properties
Czasopismo naukowe
Tytuł :
[Efficacy and safety of paclitaxel liposomes compared to paclitaxel combined with platinum in concurrent chemoradiotherapy for unresectable cervical carcinoma: a Meta-analysis].
Autorzy :
Ma XH; Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University, Jinan 250063, China.
Guo K; Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University, Jinan 250063, China.
Dong WL; Department of Data Science and Big Data Statistics, School of Statistics, Renmin University of China, Beijing 100872, China.
Jiang J; Department of Gynecology and Obstetrics, Qilu Hospital of Shandong University, Jinan 250063, China.
Pokaż więcej
Źródło :
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2021 Oct 23; Vol. 43 (10), pp. 1132-1139.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Carcinoma*
Paclitaxel*
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemoradiotherapy ; Humans ; Liposomes ; Platinum
Czasopismo naukowe
Tytuł :
Mortality Rates After Paclitaxel-Coated Device Use in Patients With Occlusive Femoropopliteal Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Autorzy :
Dinh K; Department of Vascular Surgery, Westmead Hospital, Sydney, New South Wales, Australia.; Department of Surgery, Westmead Hospital, Westmead, New South Wales, Australia.
Limmer AM; Department of Surgery, Westmead Hospital, Westmead, New South Wales, Australia.; Department of Surgery, Liverpool Hospital, Liverpool, New South Wales, Australia.
Chen AZL; Department of Surgery, Westmead Hospital, Westmead, New South Wales, Australia.
Thomas SD; Department of Surgery, Prince of Wales Hospital, Sydney, New South Wales, Australia.; Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.; The Vascular Institute, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Holden A; Department of Interventional Radiology, Auckland Hospital, Auckland, New Zealand.
Schneider PA; University of California, San Francisco, CA, USA.
Varcoe RL; Department of Surgery, Prince of Wales Hospital, Sydney, New South Wales, Australia.; Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.; The Vascular Institute, Prince of Wales Hospital, Sydney, New South Wales, Australia.
Pokaż więcej
Źródło :
Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists [J Endovasc Ther] 2021 Oct; Vol. 28 (5), pp. 755-777. Date of Electronic Publication: 2021 Jun 09.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Paclitaxel*/adverse effects
Peripheral Arterial Disease*/therapy
Coated Materials, Biocompatible ; Humans ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death.
Autorzy :
Duan XC; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Peng LY; Tianjin Key Laboratory on Technologies Enabling Development Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, People's Republic of China.
Yao X; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Xu MQ; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Li H; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Zhang SQ; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Li ZY; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Wang JR; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Feng ZH; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Wang GX; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Liao A; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Chen Y; Tianjin Key Laboratory on Technologies Enabling Development Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, People's Republic of China.
Zhang X; Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
Pokaż więcej
Źródło :
Drug delivery [Drug Deliv] 2021 Dec; Vol. 28 (1), pp. 800-813.
Typ publikacji :
Journal Article
MeSH Terms :
Albumins/*pharmacology
Antineoplastic Agents/*pharmacology
Immunogenic Cell Death/*drug effects
Inflammation Mediators/*metabolism
Nanoparticles/*chemistry
Paclitaxel/*pharmacology
Albumins/administration & dosage ; Animals ; Antineoplastic Agents/administration & dosage ; B7-H1 Antigen/immunology ; Calreticulin/drug effects ; Cell Line, Tumor ; Female ; HMGB1 Protein/drug effects ; Humans ; Mice ; Mice, Inbred BALB C ; Paclitaxel/administration & dosage ; Propionates/chemistry ; Up-Regulation ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
The anti-ovarian cancer effect of RPV modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells and tumor-bearing mice.
Autorzy :
Zhang L; School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China.
Kong L; School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China.
He SY; School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China.
Liu XZ; School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China.
Liu Y; School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China.
Zang J; School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China.
Ju RJ; Department of Pharmaceutical Engineering, Beijing Institute of Petrochemical Technology, Beijing 102617, China. Electronic address: .
Li XT; School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian 116600, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Nov 15; Vol. 285, pp. 120013. Date of Electronic Publication: 2021 Oct 03.
Typ publikacji :
Journal Article
MeSH Terms :
Cell-Penetrating Peptides*
Antineoplastic Agents/*administration & dosage
Lignans/*administration & dosage
Ovarian Neoplasms/*drug therapy
Paclitaxel/*administration & dosage
Polycyclic Compounds/*administration & dosage
Animals ; Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Cyclooctanes/administration & dosage ; Cyclooctanes/chemistry ; Female ; Humans ; Lignans/chemistry ; Liposomes ; Mice ; Mice, Inbred BALB C ; Paclitaxel/chemistry ; Polycyclic Compounds/chemistry ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma.
Autorzy :
Naruse T; Department of Clinical Oral Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan; .
Yanamoto S; Department of Clinical Oral Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Otsuru M; Department of Clinical Oral Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Yamakawa N; Department of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Japan.
Kirita T; Department of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Japan.
Shintani Y; Department of Oral and Maxillofacial Surgery, Wakayama Medical University, Wakayama, Japan.
Matsumura T; Department of Oral and Maxillofacial Surgery, Wakayama Medical University, Wakayama, Japan.
Okura M; First Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Osaka University, Osaka, Japan.; Oral and Maxillofacial Surgery, Saiseikai Matsusaka General Hospital, Matsusaka, Japan.
Sasaki M; Department of Oral and Maxillofacial Surgery, Tokai University School of Medicine, Isehara, Japan.
Ota Y; Department of Oral and Maxillofacial Surgery, Tokai University School of Medicine, Isehara, Japan.
Yamada SI; Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Kurita H; Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Umeda M; Department of Clinical Oral Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Pokaż więcej
Corporate Authors :
JAPAN ORAL ONCOLOGY GROUP (JOOG)
Źródło :
Anticancer research [Anticancer Res] 2021 Nov; Vol. 41 (11), pp. 5785-5791.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study
MeSH Terms :
Neoplasm Recurrence, Local*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Cetuximab/*administration & dosage
Mouth Neoplasms/*drug therapy
Paclitaxel/*administration & dosage
Squamous Cell Carcinoma of Head and Neck/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cetuximab/adverse effects ; Disease Progression ; Drug Administration Schedule ; Female ; Humans ; Japan ; Male ; Middle Aged ; Mouth Neoplasms/mortality ; Mouth Neoplasms/pathology ; Paclitaxel/adverse effects ; Progression-Free Survival ; Retrospective Studies ; Squamous Cell Carcinoma of Head and Neck/mortality ; Squamous Cell Carcinoma of Head and Neck/secondary ; Time Factors
Czasopismo naukowe
Tytuł :
Genetic, biochemical and histopathological evaluations of thymoquinone on male reproduction system damaged by paclitaxel in Wistar rats.
Autorzy :
Moradi Maryamneghari S; Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Shokri-Asl V; Department of Reproductive Biology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Abdolmaleki A; Department of Anatomical Sciences, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Jalili C; Department of Anatomical Sciences, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Pokaż więcej
Źródło :
Andrologia [Andrologia] 2021 Nov; Vol. 53 (10), pp. e14192. Date of Electronic Publication: 2021 Jul 26.
Typ publikacji :
Journal Article
MeSH Terms :
Paclitaxel*/adverse effects
Sperm Motility*
Animals ; Antioxidants/metabolism ; Benzoquinones ; Male ; Molecular Biology ; Oxidative Stress ; Rats ; Rats, Wistar ; Reproduction ; Spermatozoa ; Testis/metabolism ; Testosterone/metabolism
Czasopismo naukowe
Tytuł :
Synthesis and Anti-cancer Activity of Paclitaxel-Coumarin Conjugate.
Autorzy :
Song Z; College of Pharmaceutical Sciences, Anhui Xinhua University, Hefei 230088, China.
Lu Q; Proctology Department, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210022, China.
Tao A; College of Pharmaceutical Sciences, Anhui Xinhua University, Hefei 230088, China.
Wu T; Proctology Department, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210022, China.
Pokaż więcej
Źródło :
Current organic synthesis [Curr Org Synth] 2021 Oct 26; Vol. 18 (6), pp. 587-591.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Coumarins*/pharmacology
Paclitaxel*/pharmacology
Apoptosis ; Cell Line, Tumor ; Tubulin
Czasopismo naukowe
Tytuł :
Heptamethine Cyanine Dye MHI-148-Mediated Drug Delivery System to Enhance the Anticancer Efficiency of Paclitaxel.
Autorzy :
Raveendran A; Department of Materials Science & Engineering, Chonnam National University, Gwangju, 61186, Republic of Korea.
Poilil Surendran S; Department of Biomedical Sciences, Chonnam National University Medical School, Hwasun, 58128, Republic of Korea.
Ser J; Department of Materials Science & Engineering, Chonnam National University, Gwangju, 61186, Republic of Korea.
Alam K; Department of Materials Science & Engineering, Chonnam National University, Gwangju, 61186, Republic of Korea.
Cho H; Department of Materials Science & Engineering, Chonnam National University, Gwangju, 61186, Republic of Korea.
Jeong YY; Department of Radiology, Chonnam National University Hwasun Hospital, Hwasun, 58128, Republic of Korea.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2021 Oct 21; Vol. 16, pp. 7169-7180. Date of Electronic Publication: 2021 Oct 21 (Print Publication: 2021).
Typ publikacji :
Journal Article
MeSH Terms :
Nanoparticles*
Paclitaxel*
Animals ; Carbocyanines ; Cell Line, Tumor ; Drug Delivery Systems ; Indoles ; Mice ; Mice, Nude ; NIH 3T3 Cells ; Tissue Distribution
Czasopismo naukowe
Tytuł :
N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma.
Autorzy :
Li T; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin, 300457, China.
Yu P; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin, 300457, China.
Chen Y; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin, 300457, China.
Sun B; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin, 300457, China.
Dong P; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin, 300457, China.
Zhu T; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin, 300457, China; CanSino Biologics Inc., Tianjin Enterprise Key Laboratory of Respiratory Bacterial Recombination and Conjugated Vaccine, Tianjin, 300457, China.
Meng X; China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, Key Laboratory of Industrial Fermentation Microbiology of Ministry of Education, Tianjin, 300457, China. Electronic address: .
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113605. Date of Electronic Publication: 2021 Jun 05.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Delivery Systems*
Acetylgalactosamine/*chemistry
Antineoplastic Agents, Phytogenic/*pharmacology
Carcinoma, Hepatocellular/*drug therapy
Liver Neoplasms/*drug therapy
Nanoparticles/*chemistry
Paclitaxel/*pharmacology
Antineoplastic Agents, Phytogenic/chemistry ; Carcinoma, Hepatocellular/pathology ; Cell Cycle/drug effects ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Hep G2 Cells ; Humans ; Liposomes/chemistry ; Liver Neoplasms/pathology ; Molecular Structure ; Paclitaxel/chemistry ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
Autorzy :
Zhao L; School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Liang L; School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Guo M; School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Li M; School of Biosciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Yu X; School of Biosciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Wang Y; School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Wang Y; School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Pokaż więcej
Źródło :
Current topics in medicinal chemistry [Curr Top Med Chem] 2021 Oct 05; Vol. 21 (14), pp. 1268-1284.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Phytogenic/*pharmacokinetics
Carcinoma, Hepatocellular/*drug therapy
Glycyrrhetinic Acid/*chemistry
Liver Neoplasms/*drug therapy
Magnetite Nanoparticles/*chemistry
Nanoparticles/*chemistry
Paclitaxel/*pharmacokinetics
Animals ; Antineoplastic Agents, Phytogenic/chemistry ; Apoptosis/drug effects ; Carcinoma, Hepatocellular/pathology ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Drug Screening Assays, Antitumor ; Hep G2 Cells ; Humans ; Liposomes/chemistry ; Liver Neoplasms/pathology ; Liver Neoplasms, Experimental/drug therapy ; Liver Neoplasms, Experimental/pathology ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Paclitaxel/chemistry ; Particle Size
Czasopismo naukowe
Tytuł :
Editor's Choice - Paclitaxel Coated Balloon Angioplasty vs. Plain Balloon Angioplasty for Haemodialysis Arteriovenous Access Stenosis: A Systematic Review and a Time to Event Meta-Analysis of Randomised Controlled Trials.
Autorzy :
Han A; Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: .
Park T; Department of Surgery, Gyeongsang National University School of Medicine, Jinju, South Korea. Electronic address: .
Kim HJ; Institute for Evidence Based Medicine, Korea University College of Medicine, Seoul, South Korea.
Min S; Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea.
Ha J; Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea.
Min SK; Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: .
Pokaż więcej
Źródło :
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery [Eur J Vasc Endovasc Surg] 2021 Oct; Vol. 62 (4), pp. 597-609. Date of Electronic Publication: 2021 Aug 20.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
MeSH Terms :
Coated Materials, Biocompatible*
Renal Dialysis*
Vascular Access Devices*
Angioplasty, Balloon/*instrumentation
Arteriovenous Shunt, Surgical/*adverse effects
Cardiovascular Agents/*administration & dosage
Graft Occlusion, Vascular/*therapy
Paclitaxel/*administration & dosage
Aged ; Aged, 80 and over ; Angioplasty, Balloon/adverse effects ; Angioplasty, Balloon/mortality ; Arteriovenous Shunt, Surgical/mortality ; Cardiovascular Agents/adverse effects ; Female ; Graft Occlusion, Vascular/etiology ; Graft Occlusion, Vascular/mortality ; Graft Occlusion, Vascular/physiopathology ; Humans ; Male ; Middle Aged ; Paclitaxel/adverse effects ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome ; Vascular Patency
Czasopismo naukowe
Tytuł :
FV-429 enhances the efficacy of paclitaxel in NSCLC by reprogramming HIF-1α-modulated FattyAcid metabolism.
Autorzy :
Guo Y; School of Biopharmacy, China Pharmaceutical University, #639 Longmian Avenue, Nanjing, 211198, People's Republic of China.
Yang L; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, People's Republic of China.
Guo W; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, People's Republic of China.
Wei L; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, People's Republic of China. Electronic address: .
Zhou Y; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, People's Republic of China. Electronic address: .
Pokaż więcej
Źródło :
Chemico-biological interactions [Chem Biol Interact] 2021 Dec 01; Vol. 350, pp. 109702. Date of Electronic Publication: 2021 Oct 12.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*metabolism
Flavonoids/*administration & dosage
Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism
Lung Neoplasms/*drug therapy
Lung Neoplasms/*metabolism
Paclitaxel/*administration & dosage
A549 Cells ; Active Transport, Cell Nucleus/drug effects ; Animals ; Antineoplastic Agents, Phytogenic/administration & dosage ; Antineoplastic Agents, Phytogenic/toxicity ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Drug Synergism ; Fatty Acids/metabolism ; Flavonoids/toxicity ; G2 Phase Cell Cycle Checkpoints/drug effects ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Paclitaxel/toxicity ; Tumor Hypoxia/drug effects ; Wnt Signaling Pathway/drug effects ; Xenograft Model Antitumor Assays ; beta Catenin/metabolism
Czasopismo naukowe
Tytuł :
Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
Autorzy :
Georgy JT
Singh A
John AO
Joel A
Andrews AG
Thumaty DB
Rebekah G
Sigamani E
Chandramohan J
Manipadam MT
Cherian AJ
Abraham DT
Paul MJ
Balakrishnan R
Backianathan S
Chacko RT
Pokaż więcej
Transliterated Title :
Patologická odpoveď a klinické výsledky při léčbě operabilního triple negativního karcinomu prsu cisplatinou přidanou k standardní neoadjuvantní chemoterapii.
Źródło :
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti [Klin Onkol] 2021 Winter; Vol. 34 (1), pp. 49-55.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Cisplatin/*administration & dosage
Cyclophosphamide/*administration & dosage
Doxorubicin/*administration & dosage
Epirubicin/*administration & dosage
Paclitaxel/*administration & dosage
Triple Negative Breast Neoplasms/*drug therapy
Adult ; Anemia/chemically induced ; Antineoplastic Agents/adverse effects ; Cisplatin/adverse effects ; Cyclophosphamide/adverse effects ; Doxorubicin/adverse effects ; Drug Therapy, Combination ; Epirubicin/adverse effects ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Staging ; Paclitaxel/adverse effects ; Retrospective Studies ; Treatment Outcome ; Triple Negative Breast Neoplasms/pathology ; Triple Negative Breast Neoplasms/surgery ; Young Adult
Czasopismo naukowe
Tytuł :
Self-assembly of chiral foldamers with alternating hydrophilic and hydrophobic side chains into acid-sensitive and solvent-exchangeable vesicular particles.
Autorzy :
Zhao Z; State Key Laboratory of Polymer and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, 130022, Changchun, China. .; University of Science and Technology of China, 230026, Hefei, China.
Bian Z; Key Laboratory of Polyoxometalate Science of the Ministry of Education, Faculty of Chemistry, Northeast Normal University, 5268 Renmin Street, 130024, Changchun, China. .
Chen Y; State Key Laboratory of Polymer and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, 130022, Changchun, China. .
Xie Z; State Key Laboratory of Polymer and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, 130022, Changchun, China. .; University of Science and Technology of China, 230026, Hefei, China.
Kang C; State Key Laboratory of Polymer and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, 130022, Changchun, China. .; University of Science and Technology of China, 230026, Hefei, China.
Gao L; State Key Laboratory of Polymer and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, 5625 Renmin Street, 130022, Changchun, China. .; University of Science and Technology of China, 230026, Hefei, China.
Zhu G; Key Laboratory of Polyoxometalate Science of the Ministry of Education, Faculty of Chemistry, Northeast Normal University, 5268 Renmin Street, 130024, Changchun, China. .
Pokaż więcej
Źródło :
Soft matter [Soft Matter] 2021 Nov 17; Vol. 17 (44), pp. 10073-10079. Date of Electronic Publication: 2021 Nov 17.
Typ publikacji :
Journal Article
MeSH Terms :
Paclitaxel*
Water*
Hydrophobic and Hydrophilic Interactions ; Solvents
Czasopismo naukowe
Tytuł :
Predictors of Favorable Angiographic Outcomes After Drug-Coated Balloon Use for de novo Small Vessel Coronary Disease (DCB-ONLY).
Autorzy :
Kang WC; Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
Park SM; Eulji University Hospital, College of Medicine, Seoul, Republic of Korea.
Jang AY; Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
Oh PC; Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
Shin ES; Ulsan Medical Center, Ulsan Hospital, Ulsan, Republic of Korea.
Yu CW; Korea University Anam Hospital, Seoul, Republic of Korea.
Oh SJ; NHIS Ilsan Hospital, Goyang, Republic of Korea.
Kim YH; Kangwon National University School of Medicine, Chuncheon, Republic of Korea.
Won H; Chung-Ang University Hospital, Seoul, Republic of Korea.
Lee SR; Chonbuk National University, School of Medicine, Jeonju, Republic of Korea.
Lee SY; Chungbuk National University, School of Medicine, Cheongju, Republic of Korea.
Hong YJ; Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea.
Lee SY; Inje University Ilsan Paik Hospital, Goyang, Republic of Korea.
Kim BO; Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.
Kim SW; Chung-Ang University Hospital, Seoul, Republic of Korea.
Pokaż więcej
Corporate Authors :
DCB-ONLY Investigators
Źródło :
Angiology [Angiology] 2021 Nov; Vol. 72 (10), pp. 986-993. Date of Electronic Publication: 2021 May 13.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Cardiac Catheters*
Coated Materials, Biocompatible*
Coronary Angiography*
Angioplasty, Balloon, Coronary/*instrumentation
Cardiovascular Agents/*administration & dosage
Coronary Artery Disease/*therapy
Coronary Vessels/*diagnostic imaging
Paclitaxel/*administration & dosage
Aged ; Angioplasty, Balloon, Coronary/adverse effects ; Cardiovascular Agents/adverse effects ; Coronary Artery Disease/diagnostic imaging ; Coronary Artery Disease/mortality ; Coronary Restenosis/diagnostic imaging ; Coronary Restenosis/etiology ; Equipment Design ; Female ; Humans ; Male ; Middle Aged ; Paclitaxel/adverse effects ; Predictive Value of Tests ; Prospective Studies ; Registries ; Republic of Korea ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
AIE-active polymeric micelles based on modified chitosan for bioimaging-guided targeted delivery and controlled release of paclitaxel.
Autorzy :
Shi H; Key Laboratory of Functional Inorganic Materials Chemistry (Ministry of Education), School of Chemistry and Material Science, Heilongjiang University, Harbin 150080, China.
Liang N; College of Chemistry & Chemical Engineering, Harbin Normal University, Harbin 150025, China. Electronic address: .
Liu J; Key Laboratory of Functional Inorganic Materials Chemistry (Ministry of Education), School of Chemistry and Material Science, Heilongjiang University, Harbin 150080, China.
Li S; Key Laboratory of Functional Inorganic Materials Chemistry (Ministry of Education), School of Chemistry and Material Science, Heilongjiang University, Harbin 150080, China.
Gong X; Key Laboratory of Functional Inorganic Materials Chemistry (Ministry of Education), School of Chemistry and Material Science, Heilongjiang University, Harbin 150080, China.
Yan P; Key Laboratory of Functional Inorganic Materials Chemistry (Ministry of Education), School of Chemistry and Material Science, Heilongjiang University, Harbin 150080, China.
Sun S; Key Laboratory of Functional Inorganic Materials Chemistry (Ministry of Education), School of Chemistry and Material Science, Heilongjiang University, Harbin 150080, China. Electronic address: .
Pokaż więcej
Źródło :
Carbohydrate polymers [Carbohydr Polym] 2021 Oct 01; Vol. 269, pp. 118327. Date of Electronic Publication: 2021 Jun 10.
Typ publikacji :
Journal Article
MeSH Terms :
Micelles*
Antineoplastic Agents/*therapeutic use
Chitosan/*analogs & derivatives
Drug Carriers/*chemistry
Fluorescent Dyes/*chemistry
Neoplasms/*drug therapy
Paclitaxel/*therapeutic use
Animals ; Antineoplastic Agents/pharmacology ; Carbohydrate Sequence ; Cell Line, Tumor ; Chitosan/chemical synthesis ; Drug Carriers/chemical synthesis ; Drug Liberation ; Female ; Fluorescent Dyes/chemical synthesis ; Humans ; Mice ; Neoplasms/diagnostic imaging ; Neoplasms/pathology ; Paclitaxel/pharmacology
Czasopismo naukowe
Tytuł :
Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel.
Autorzy :
Huang JW; School of Pharmacy, College of Medicine, National Taiwan University, Taipei City, Zhongzheng Dist., Taiwan.
Kuo CH; School of Pharmacy, College of Medicine, National Taiwan University, Taipei City, Zhongzheng Dist., Taiwan.; The Metabolomics Core Laboratory, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei City, Zhongzheng Dist., Taiwan.
Kuo HC; The Metabolomics Core Laboratory, Centers of Genomic and Precision Medicine, National Taiwan University, Taipei City, Zhongzheng Dist., Taiwan.
Shih JY; Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Zhongzheng Dist., Taiwan.
Tsai TW; School of Pharmacy, College of Medicine, National Taiwan University, Taipei City, Zhongzheng Dist., Taiwan.
Chang LC; School of Pharmacy, College of Medicine, National Taiwan University, Taipei City, Zhongzheng Dist., Taiwan.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2021 Mar 19; Vol. 16 (3), pp. e0248942. Date of Electronic Publication: 2021 Mar 19 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Metabolomics*
Albumins/*toxicity
Fatty Acids/*metabolism
Neurotoxins/*toxicity
Paclitaxel/*toxicity
Solvents/*chemistry
Acyl-CoA Dehydrogenase/metabolism ; Albumin-Bound Paclitaxel/pharmacology ; Carnitine/analogs & derivatives ; Carnitine/metabolism ; Cell Differentiation ; Cell Line, Tumor ; Cell Survival/drug effects ; Humans ; Oxidation-Reduction
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies